The new guidelines describe the features of chronic pulmonary aspergillosis (CPA) and provide comprehensive treatment recommendations.
Researchers designed a case-control study using de-identified commercial health claim information in the United States from January 1, 2007, to December 31, 2009.
Treatment was tested in critically ill patients with ICU-acquired sepsis, multiple Candida colonization, and multiple organ failure.
Flu may represent a novel host risk factor for this invasive fungal infection.
The updated guidelines focus on the diagnosis and treatment of the major forms of aspergillosis: allergic, chronic and invasive, the latter which kills 40% to 80% of those with widespread infection.
Drs Tapper and Crum-Cianflone discuss aspergillosis, an emerging complication of severe influenza infections.
Rapid identification of Candida auris is crucial in order to implement appropriate precautions and avoid transmission to other patients.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Climate Change: Effects on the Incidence and Distribution of Infectious Diseases
- Improving Campaigns Regarding the Value of Adult Vaccines
- Seminal HPV Infection Prevalent Worldwide, May Affect Male Fertility
- Pausing ART to Identify Biomarkers for HIV RNA Rebound: Safety and Ethical Considerations
- MicroRNAs in Infectious Disease: Emerging Clinical Applications
- Efficacy of Direct-Acting Antivirals for HCV Clearance in Older Adults
- SVR Achieved With Sofosbuvir, Grazoprevir/Elbasvir Plus Ribavirin in HCV
- First Oral Smallpox Treatment Submitted to FDA for NDA
- Trends in Meningococcal Disease Following MenACWY Vaccine Introduction
- Clinician Accuracy Evaluated for Lyme Disease